KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to 0.7.

  • Vertex Pharmaceuticals' Equity Ratio fell 88.69% to 0.7 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.7, marking a year-over-year decrease of 88.69%. This contributed to the annual value of 0.73 for FY2024, which is 584.36% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Equity Ratio stood at 0.7 for Q3 2025, which was down 88.69% from 0.71 recorded in Q2 2025.
  • Vertex Pharmaceuticals' Equity Ratio's 5-year high stood at 0.78 during Q3 2022, with a 5-year trough of 0.7 in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' median Equity Ratio value was 0.76 (recorded in 2021), while the average stood at 0.75.
  • In the last 5 years, Vertex Pharmaceuticals' Equity Ratio soared by 494.9% in 2021 and then plummeted by 752.84% in 2024.
  • Vertex Pharmaceuticals' Equity Ratio (Quarter) stood at 0.75 in 2021, then rose by 1.94% to 0.77 in 2022, then rose by 0.9% to 0.77 in 2023, then dropped by 5.84% to 0.73 in 2024, then dropped by 4.35% to 0.7 in 2025.
  • Its Equity Ratio stands at 0.7 for Q3 2025, versus 0.71 for Q2 2025 and 0.72 for Q1 2025.